Publication|Videos|October 3, 2024
FSP Partnership: A Foundation for Innovation and Patient-Guided Development
Author(s)PAREXEL
Liz Rogers, VP and Head of Global Site and Study Operations at Pfizer, discusses Pfizer's partnership with Parexel and transition to a functional service provider (FSP) model.
- Transitioning to an FSP model, strategically allocating resources, and leveraging partnerships introduced a more streamlined and efficient model, enhancing resource efficiency and flexibility. The approach has enabled the sponsor (Pfizer) to tap into specialized expertise while maintaining control and oversight of clinical operations.
- Growing core capabilities in site and study management further enhanced site performance and oversight of quality and compliance. Further strengthening relationships with sites is key to the strategy alongside supporting novel recruitment models, shifting to remote monitoring, and focusing on fewer, higher-performing clinical sites.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Content
Trending on Applied Clinical Trials Online
1
Praxis Reports Positive Phase III Results for Ulixacaltamide in Essential Tremor
2
Setting the Limits of Autonomy with Autonomous Agents for Clinical Research
3
Adaptive Trial Design as a Pathway to Faster Development
4
Eli Lilly’s Orforglipron Shows Superior Efficacy Across Multiple Phase III Trials in Type 2 Diabetes
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
